Eloralintide vs cagrilintide is a comparison of two weekly amylin-pathway injections. Eloralintide is made by Eli Lilly and cagrilintide by Novo Nordisk.

Both are once-weekly amylin-pathway injections, and neither is approved alone. Eloralintide (Lilly) prefers one amylin receptor, AMY1R, 12-fold over the calcitonin receptor in cell tests[1]. Cagrilintide (Novo Nordisk) acts on amylin and calcitonin receptors without that preference[2]. Alone, eloralintide reached up to −20.1% body weight at 48 weeks in phase 2[3]; cagrilintide alone reached −11.5% at 68 weeks in a phase 3 arm (as cited by Briere 2025[1]). No head-to-head human trial exists (ClinicalTrials.gov, searched 2026-11-17).
Eloralintide: best evidence is a human RCT (phase 2, 48 weeks). Phase 3 is running.
Cagrilintide: best evidence is human RCTs (phase 2, and a phase 3 arm inside REDEFINE 1). Not approved on its own.
| Feature | Eloralintide | Cagrilintide |
|---|---|---|
| Developer | Eli Lilly (code LY3841136) | Novo Nordisk |
| How it works | Selective amylin receptor agonist: AMY1R 12-fold over the calcitonin receptor in cells[1] | Non-selective amylin and calcitonin receptor agonist (review)[2] |
| Status | Phase 3 (ENLIGHTEN, 8 trials registered); not approved anywhere | Not approved alone. Its combination with semaglutide (CagriSema) was submitted to FDA on 2025-12-18 (Novo Nordisk US press release); no FDA decision found as of 2026-11-17 |
| Latest phase with results | Phase 2[3] | Phase 3 arm in REDEFINE 1 (cited in[1]) |
| Weight change, alone | Up to −20.1% at 48 weeks vs −0.4% placebo (efficacy estimand)[3] | −6.0% to −10.8% at 26 weeks vs −3.0% placebo[4]; −11.5% at 68 weeks in REDEFINE 1 (cited in[1]) |
| Half-life | 12.9–15.3 days, single dose[1] | 6.6–8.1 days, as cited in the same paper[1] |
| Nausea in phase 2 | 11–64% by arm vs 14% placebo[3] | 20–47% by arm vs 18% placebo[4] |
| Signature side effect | Fatigue, 0–46% by arm vs 12% placebo[3] | No data on this site yet |
| Combination product | EloraTZP (with tirzepatide): phase 2b, up to −23.3% at 48 weeks (Lilly press release, 2026-09-30)[5] | CagriSema (with semaglutide): −20.4% vs −3.0% at 68 weeks[6] |
Cross-trial table. The trials differ in length (26, 48 and 68 weeks), population and estimand, so the numbers in one row are not a head-to-head result.
Amylin is a hormone released with insulin. Drugs that copy it slow stomach emptying and signal fullness. Both drugs act on this pathway, which is why neither is a GLP-1 drug.
The difference is which receptors they switch on. In human cell tests, eloralintide activated the AMY1 receptor 12-fold more strongly than the calcitonin receptor and 11-fold more strongly than AMY3R. In rats the pattern was different (cell data)[1]. Cagrilintide acts on amylin and calcitonin receptors alike[2]. We have not found cagrilintide figures from the same cell test, so the two cannot be put on one scale.
Separate trials: not a head-to-head comparison
Scale: 0–15.3 days
Eloralintide from its phase 1 study; cagrilintide as cited in the same paper[1]. How long a drug stays in the body. This is not a schedule.
Names that get mixed up: CagriSema is cagrilintide plus semaglutide in one product. EloraTZP is eloralintide plus tirzepatide. Eloralintide's code name is LY3841136.
| Trial | Drug | Weeks | Weight change (top arm) | Placebo | Source |
|---|---|---|---|---|---|
| Phase 2 (Human RCT) | Eloralintide alone | 48 | −20.1% (efficacy) | −0.4% | [3] |
| Phase 2 (Human RCT) | Cagrilintide alone | 26 | −6.0% to −10.8% across arms | −3.0% | [4] |
| REDEFINE 1 (Human RCT) | Cagrilintide alone | 68 | −11.5% | no data here | Cited in[1] |
| Phase 2b, type 2 diabetes (Company press release) | EloraTZP | 48 | −23.3% (efficacy) | −3.0% | Lilly, 2026-09-30[5] |
| REDEFINE 1 (Human RCT) | CagriSema | 68 | −20.4% (treatment-policy) | −3.0% | [6] |
Each drug alone and in its combination product. Different trials, lengths and estimands: read each row on its own.
Two cautions. The EloraTZP figure is from a press release and was in people with type 2 diabetes, who usually lose less weight than people without it. And comparing eloralintide alone with CagriSema mixes a single drug with a combination, which several ranking pages do.
In the eloralintide 9 mg arm, nausea was reported by 33% and fatigue by 43%, against 14% and 12% on placebo (human randomised trial)[3]. See all trial arms below for each dose tested.
Cagrilintide's phase 2 trial reported nausea in 20–47% of people across arms, against 18% on placebo[4]. In REDEFINE 1, gastrointestinal side effects were reported by 79.6% on CagriSema and 39.9% on placebo[6].
Only the combinations below have been tested in trials. EloraTZP pairs eloralintide with tirzepatide: phase 2b has reported (Lilly press release, 2026-09-30)[5] and two phase 3 trials are registered[7][8]. CagriSema pairs cagrilintide with semaglutide[6].
ClinicalTrials.gov, searched 2026-11-17
More on EloraTZP is on the eloralintide page. For the other Lilly comparison, see eloralintide vs retatrutide.
Scale: 0–20.1%
Published trial arms, efficacy estimand (as if everyone stayed on treatment). n = 263 adults with obesity or overweight, no type 2 diabetes[3]. Not a dose recommendation.
Scale: 0–70%
From the Lancet abstract[3], which rounds to whole numbers.
Scale: 0–70%
Same trial[3].
| Claim | Verdict | What the source says |
|---|---|---|
| Cagrilintide alone reached "mid-teens" weight loss in REDEFINE 1 (a ranking comparison page) | Wrong | −11.5% at 68 weeks, as cited in[1] |
| Eloralintide causes less nausea than cagrilintide | No human source | Only a Lilly rat study on taste avoidance[1] |
| Eloralintide will replace cagrilintide | No source | No trial compares them; neither is approved alone |
Cagrilintide phase 2 published: −6.0% to −10.8% at 26 weeks.
Lau et al., Lancet 2021[4] Human randomised trialREDEFINE 1 (CagriSema) published in NEJM: −20.4% vs −3.0% at 68 weeks.
Garvey et al., NEJM 2025[6] Human randomised trialEloralintide phase 2 published online in the Lancet.
Billings et al., Lancet 2025[3] Human randomised trialEloraTZP phase 2b results announced; not yet peer-reviewed.
Lilly press release[5] Company press releaseFDA states cagrilintide cannot be used in compounding under federal law.
FDA statement on unapproved GLP-1 drugs[10] RegulatorEarliest estimated primary completion of an eloralintide phase 3 trial (ENLIGHTEN-2).
ClinicalTrials.gov[9] Trial registryCagriSema was submitted to FDA on 2025-12-18 (Novo Nordisk US press release). Novo guided a decision in the fourth quarter of 2026. We found no approval or rejection as of 2026-11-17 and will update this page when one is published.
Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.
No. It is an amylin receptor agonist that prefers the AMY1 receptor[1]. Lilly is testing it with tirzepatide, which does act on GLP-1 receptors.
No. CagriSema is cagrilintide combined with semaglutide. In REDEFINE 1 it reached −20.4% at 68 weeks vs −3.0% on placebo[6].
There is no human comparison. Nausea in phase 2 was 11–64% by arm for eloralintide vs 14% placebo, and 20–47% for cagrilintide vs 18% placebo, in different trials. The only direct comparison is a rat study.
No trial has tested cagrilintide with tirzepatide. The tested combinations are cagrilintide with semaglutide (CagriSema) and eloralintide with tirzepatide (EloraTZP).
No. Eloralintide is in phase 3. Cagrilintide is not approved alone, and FDA says it cannot be used in compounding[10]. CagriSema awaits an FDA decision.
No date has been announced. The earliest phase 3 trial is estimated to reach primary completion in January 2028[9], and a filing would come after that.
There is no source for that. Both are still investigational on their own, and no trial compares them.